Retroscreen Share Discussion Threads

[m.t.glass] 18/3/2013 08:50

applicable to this stock:

"The Government is set to allow Aim listed shares to be held within an Isa.. ... The plans, which were suggested in last year's Autumn Statement, are designed to encourage more investment in growing companies and create an "important capital injection" for small to medium-sized enterprise equity markets... ...The new rules, expected to be introduced in the Autumn, will allow investors to invest their full Isa allowance, currently £11,280. into Aim shares..."

[m.t.glass] 14/3/2013 15:52

and a brief reference to Retroscreen Virology in this story:

[m.t.glass] 14/3/2013 15:45

An earlier article (London Evening Standard, 1st March):


Human guinea pigs are being paid thousands to be infected with flu as part of a London-based clinical trial.

Students and others are signing up to take part in the Whitechapel-based FluCamp, which studies treatments for flu and the common cold. It is now expanding to other sites after a rise in the number of volunteers.

After initial blood and health tests, suitable candidates are infected with a virus and spend between 10 and 18 days on the unit. On completing the study they are paid up to £3,750.

Volunteer Christopher Smith, 22, who is studying Biomedical Science at Queen Mary, University of London, said: "The chance to put your feet up for two weeks, be a bit ill and get paid for it is very attractive to a student.

"Plus it's just the flu so you can crawl into bed and catch up on DVD box sets for a while. Some of the money would go towards accommodation for university and the rest for snowboarding."

Chief scientific officer Rob Lambkin-Williams did not think the payment was excessive. He said: "They come to our facility, it's very nice. It's like a hotel, they've all got en suite rooms etc.

"But at the end of the day we are asking people to give up two weeks of their lives, plus we are asking them to come back several times afterwards to make sure they are perfectly healthy."

There has also been an increase in interest from drug companies hoping to develop their products.

Mr Lambkin-Williams said: "We are spreading across four sites now." They are in London, Ely, Cambridge and Manchester.

He added that although the study is open to those aged 18 to 45, volunteers tended to be in their twenties and early thirties. "We have students, Australian barmen, South African rugby players - it is a real mix." FluCamp is run by Retroscreen Virology Ltd. Queen Mary College and the University of London owns a small proportion of shares in the company. It started with eight volunteers in a hall of residence at the university.

Goldsmiths student Emily Chapple, 20, has posted a video diary of her FluCamp experience on YouTube.

She said: "I like my own company and I had a lot of reading and studying to do uni-wise so it was a really constructive time for me."

[elevata] 14/3/2013 10:41

Hi m.t.glass, yep. I was on the latest screening.

[m.t.glass] 14/3/2013 09:42

elevata - r u one of the 20 mentioned here?:

Coughs and sneezes spread diseases, but how? CDC backed influenza transmission study underway.

On the 7th of March 2013 Retroscreen Virology (@flucamp), the University of Nottingham and collaborators, began a major study aimed at understanding how influenza is transmitted between people. Twenty healthy volunteers have been inoculated with a human flu virus under strictly controlled quarantine conditions. Over the next few days they will socialise with other volunteers and then scientists from the Universities of Nottingham (UK) and Maryland (USA) working in partnership with experts at Retroscreen will study the patterns of transmission as they occur. If successful the study will assist public health policy makers in designing improved interventions to prevent flu transmission in healthcare facilities and households. The study addresses an area of science acknowledged by the World Health Organization (WHO), the European Centre for Disease Prevention and Control, the US Centers for Disease Control and Prevention (CDC), and the Institute of Medicine to be a major gap in global medical knowledge.

The Influenza transmission study is a collaboration between Retroscreen, the University of Nottingham and several other academic groups from around the world. The programme is funded by the Centers For Disease Control and Prevention (CDC) in the USA. The study will aim to recruit over 130 volunteers and will be the largest ever investigation into influenza transmission.

Dr Robert Lambkin-Williams, Chief Scientific Officer at Retroscreen Virology said " This is an exciting project that will answer a very important question; it is incredible that even in the 21st century we don't understand how somebody catches flu!"

Professor Jonathan Van-Tam, University of Nottingham Health Protection and Influenza Research Group said "This is unique scientific work, conducted by an equally unique global consortium. The complex nature of the work that we are doing is truly ground-breaking. Many organisations including the WHO are eagerly awaiting our results. I feel incredibly privileged to be leading such a talented group of scientists."

Kym Denny, Chief Executive Officer at Retroscreen Virology Ltd commented: "The spread of Influenza virus is surprisingly poorly understood and this is vital research. Even before the next pandemic, respiratory illness in general and flu in particular was one of the largest drivers of cost to health provision in the developed world. The funding by the CDC illustrates the continuing importance of influenza research, and further demonstrates the flexibility and application of the Human Viral Challenge Model for research-based projects as well as studies involving new antiviral drugs and vaccines. We are delighted to be working with the University of Nottingham again, with whom we previously established the transmission model in 2009. We are tremendously excited by the study which will help us better understand how to prevent the spread of flu and inform future public health initiatives".

[m.t.glass] 14/3/2013 09:38

4-day event beginning today in Rotterdam:

Retroscreen Virology Limited, a global leader in anti-viral research, and the conduct of human viral challenge studies, is pleased to announce that the company will be represented at the XV International Symposium on Respiratory Viral Infections held at the Van der Valk Hotel Rotterdam-Blijdorp, Rotterdam, The Netherlands between 14-17 March 2013.

The Symposium is organised by The Macrae Foundation and "brings together international thought leaders, performing visionary research and developing current treatments that benefit everyone in the health science field. The symposium serves as a catalyst for discussing and debating cutting edge information, with the aim of creating an interconnected flow of worldwide research and propelling new directions in research for science, industry and government funding agencies."

The 2013 Symposium will present the practical aspects of current treatment and future prospects for respiratory viral infectious diseases through invited talks, oral abstracts and poster abstract presentations. The research carried out at Retroscreen is predominantly focused on respiratory viral infections, and this Symposium is a key event in the company's calendar.

Retroscreen will be represented by several attendees including Dr Rob Lambkin-Williams, Chief Scientific Officer, and Dr Ian Meikle, Business Development Director.

[elevata] 13/3/2013 18:36

Just been on the flu camp trialrun by Retroscreen . Seems to be a great success and they know what they are doing . I bought some straight away. Get in now because when these trials hit the headlines the shares will soar. Got to be in it to win it!

[butler4] 10/3/2013 21:58

Liamnich04. I'm looking closely at this company as reports indicating exciting new trials Could you enlighten me further Do you have much info on this Very much appreciate your comments

[liamnich04] 08/3/2013 11:23

I'm currently doing a medical trial for these at the Borne facilities - flucamp!

[andrbea] 10/1/2013 14:19

up 2%


10/01/2013 13:49:41 RVG 175.00 O 5,000
10/01/2013 11:20:48 RVG 170.00 O 29,432
10/01/2013 11:20:33 RVG 170.00 O 25,000
10/01/2013 11:19:06 RVG 170.00 O 25,000

29432 at 170 is 50k pounds

[m.t.glass] 10/1/2013 08:27

No posts on this thread in June-through-December. Only ten posts altogether while the share price doubled. I've no idea if the price has any further to go. Anyone interested in assessing its prospects?

[andrbea] 09/1/2013 13:45

2012 is set to be a transformational year for Retroscreen as the company recently announced a Trading Update indicating revenue growth for 2012 in excess of 200%.

Read more: Retroscreen Virology Chooses Deltek's Cloud ERP Solution to Support Its Rapid Growth - FierceBiotechIT

[maxwellman] 27/5/2012 13:25

anyone else looking at the company - any thoughts?

[maxwellman] 24/5/2012 22:12

nice gradual tick up anyone else got any views?

[maxwellman] 13/5/2012 20:45

was that a 250k buy on friday?

[maxwellman] 10/5/2012 22:08

Hi MT,

nice little rise today and luckily got in earlier this morning - anymore news on other possible partnerships in the pipeline !

[2baffled] 10/5/2012 21:53

Hi MT. Thank you for opening this forum.

Interesting series of 'holdings notices' filtering through.
I also note that IG have reasonable tier terms for RVG given it's a 'new-kid on the block'.

[I too have IPO ....... FTSE 250 candidate, I believe].
IC comment [is it valid?] =====>>

[m.t.glass] 03/5/2012 10:59

80p launch price opened at 87.5p

[m.t.glass] 03/5/2012 07:52

I am not yet a buyer or holder of RVG shares - just watchin'
I already hold shares in stakeholder IP Group (IPO)


GCI yesterday:

02/05/2012 Ben Jaglom

Pharma concern Retroscreen Virology Group is to join AIM this year in an IPO worth £15 million.

The Tower-Hamlets based spin-out from Queen Mary University - which is hoping to raise the amount via broker Numis -specialises in viral studies in humans, developing drugs and vaccines for a variety of viral infections. Upon admission to the junior market at a price of 80p a share the group will have a market cap of circa £32.8 million.

Retroscreen is being steered by chief executive officer Kym Denny, a veteran of the pharma sector and the former managing director of global research specialists Harrison Clinical Research. Overseeing action at Retroscreen is David Norwood, an ex-foreign exchange trader and the former CEO of stockbroker Beeson Gregory.

Funds that have subscribed to the placing include Blackrock, Lansdown Partners and Henderson Global Investors. Shareholder Queen Mary University will see its stake diluted from 8.4 per cent to 4.5 per cent following admission.

Joining at a tricky time for pharma companies on AIM, Retroscreen will have its work cut out convincing the market following the raft of disappointing IPOs that have emerged from the sector.

[m.t.glass] 03/5/2012 07:46

November 17, 2011

Peter Mansell


Retroscreen Virology (RVL), the specialist virology contract research organisation based in the UK, is poised to launch its first commercial human viral-challenge study at a new purpose-built facility completed last February at Queen Mary, University of London.

RVL has already conducted an academic study with Duke University of the US at the 1,300sq m facility, which comprises 24 quarantined bedrooms as well as clinical, laboratory, administrative and conference space.

The company is occupying a whole floor of Queen Mary BioEnterprises' (QMB) Innovation Centre on the university's Whitechapel campus in East London. It was the first anchor tenant for the Innovation Centre, a £25 million partnership between Queen Mary and the London Development Agency that offers some 3,700sq m of office and laboratory space to high-technology companies in the life sciences sector.

QMB is a wholly owned company of Queen Mary, University of London, while RVL started life as a spin-out from the same institution.

Bespoke space

The new £2 million facility gives Retroscreen bespoke space for its quarantined 'Flu Camp' trials of novel antivirals and vaccines, marking the first clinical facility dedicated to human viral challenge studies since the closure of the UK's Common Cold Institute in the 1990s.

According to Dr Rob Lambkin-Williams, chief scientific officer of Retroscreen Virology Ltd, there is no similar facility anywhere in the world conducting human viral challenge (HVC) studies on this scale. RVL also says it is unique in the range of HVC studies the company offers, spanning influenza, the common cold and respiratory syncytial virus (RSV).

As Ramsey Richmond, executive manager of the QMB Innovation Centre, noted, the bedrooms at the London facility are fitted with "quasi air-locks" separating them from the research laboratories. Quarantined conditions are further enhanced by a roof-top emergency generator and security systems to segment the facility space.

These capabilities make it easier to isolate patients, improve study efficiency and avoid the risks of existing infections being transferred that complicate HVC studies conducted in hotels or open-ward hospitals. Previously RVL relied on adapting hotel space or student accommodation for its 'Flu Camp' trials.

The company now expects to run "at least" 12 quarantines a year across the range of 'flu, common cold and RSV. Lambkin-Williams is also hoping next year to start conducting rhinovirus challenge studies in asthmatics. Norovirus studies are also in the pipeline, and the Queen Mary facility is set up to accommodate these.

The recent academic study with Duke University involved looking at the impact of 'flu in cognitive function, addressing the question of whether early intervention with antivirals can improve productivity once people are back at work after their illness.

In addition to the commercial HVC challenge study due to begin shortly at the Queen Mary facility, Retroscreen has four to five commercial trials lined up for next year.

PoC advantage

The company specialises in Phase IIa HVC studies for rapid proof of concept (PoC). According to Lambkin-Williams, it can complete these trials in six months to a year, "whereas trying to do proof of concept with a virus infection in the field is going to take you two or three years".

Companies will still need to conduct field studies but a successful PoC trial will "really guide" how these studies are designed, he adds.


In the present constrained environment, the possibility of getting a product to market one year earlier "can make a huge difference", Lambkin-Williams comments.

Nor is this just a financial gain. In Europe alone, there are still 30,000 children dying each year from respiratory syncytial virus, Lambkin-Williams points out.

[m.t.glass] 03/5/2012 07:27

.

Newly listed on AIM, May 2012, at 80p per share.

Website

They employ live human volunteers in tests. As decribed on website Home Page. Analysing pathways taken by respiratory diseases, allowing better targeting of treatments.
(So could generate controversy if a volunteer experiences problems?)

IP Group (IPO) is a significant stakeholder. Click to see all major shareholders.

"..Retroscreen Virology has developed a business system with two principal units. The first is a Clinical Services business built around Human Viral Challenge Model and the second is a Translational Research (Pre-Clinical) business, built around in-house expertise on testing antivirals and virucidals in-vitro.

The team at Retroscreen Virology are committed to creating the next generation of drugs and vaccines for a number of respiratory diseases..."